Loading...

GeNeuro SA

GNRO.PA•EURONEXT
Healthcare
Biotechnology
€0.06
€0.002(3.00%)

GeNeuro SA (GNRO.PA) Stock Overview

Explore GeNeuro SA’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 64.2/100

Key Financials

Market Cap1.6M
P/E Ratio-0.09
EPS (TTM)$-0.59
ROE2.39%
Fundamental Analysis

AI Price Forecasts

1 Week$0.09
1 Month$-1.66
3 Months$0.07
1 Year Target$0.01

GNRO.PA Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of GeNeuro SA (GNRO.PA) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 42.56, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.01.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.09 and a market capitalization of 1.6M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

42.56RSI (14)
-0.01MACD
21.36ADX
Stats data is not available for GNRO.PAStats details for GNRO.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for GNRO.PAAnalyst Recommendations details for GNRO.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is in Phase I for the treatment of chronic inflammatory demyelinating polyneuropathy. It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic labs to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.

CEO

Jesus Martin-Garcia

Employees

17

Headquarters

3 chemin du PrE-Fleuri, Plan-les-Ouates

Founded

2016

Frequently Asked Questions

;